Retinoblastoma Binding Protein 4 Modulates Temozolomide Sensitivity in Glioblastoma by Regulating DNA Repair Proteins

被引:55
作者
Kitange, Gaspar J. [1 ]
Mladek, Ann C. [1 ]
Schroeder, Mark A. [1 ]
Pokorny, Jenny C. [1 ]
Carlson, Brett L. [1 ]
Zhang, Yuji [2 ,4 ]
Nair, Asha A. [2 ]
Lee, Jeong-Heon [3 ]
Yan, Huihuang [2 ]
Decker, Paul A. [2 ]
Zhang, Zhiguo [3 ]
Sarkaria, Jann N. [1 ]
机构
[1] Mayo Clin, Dept Radiat Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Biostat & Bioinformat, Rochester, MN 55905 USA
[3] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
[4] Univ Maryland, Sch Med, Div Biostat & Bioinformat, Baltimore, MD 21201 USA
关键词
PROMOTER METHYLATION; SYNTHETIC LETHALITY; PARP INHIBITOR; IN-VITRO; CELLS; RESISTANCE; COMPLEX; GENE; EXPRESSION; MECHANISMS;
D O I
10.1016/j.celrep.2016.02.045
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Here we provide evidence that RBBP4 modulates temozolomide (TMZ) sensitivity through coordinate regulation of two key DNA repair genes critical for recovery from TMZ-induced DNA damage: methylguanine-DNA-methyltransferase (MGMT) and RAD51. Disruption of RBBP4 enhanced TMZ sensitivity, induced synthetic lethality to PARP inhibition, and increased DNA damage signaling in response to TMZ. Moreover, RBBP4 silencing enhanced TMZ-induced H2AX phosphorylation and apoptosis in GBM cells. Intriguingly, RBBP4 knockdown suppressed the expression of MGMT, RAD51, and other genes in association with decreased promoter H3K9 acetylation (H3K9Ac) and increased H3K9 tri-methylation (H3K9me3). Consistent with these data, RBBP4 interacts with CBP/p300 to form a chromatin-modifying complex that binds within the promoter of MGMT, RAD51, and perhaps other genes. Globally, RBBP4 positively and negatively regulates genes involved in critical cellular functions including tumorigenesis. The RBBP4/CBP/p300 complex may provide an interesting target for developing therapy-sensitizing strategies for GBM and other tumors.
引用
收藏
页码:2587 / 2598
页数:12
相关论文
共 50 条
[1]   Regulation of the human O6-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300 [J].
Bhakat, KK ;
Mitra, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (44) :34197-34204
[2]  
Cahill Daniel P, 2008, Clin Neurosurg, V55, P165
[3]  
Carlson Brett L, 2011, Curr Protoc Pharmacol, VChapter 14, DOI 10.1002/0471141755.ph1416s52
[4]   Downregulation of BRCA1-BRCA2-containing complex subunit 3 sensitizes glioma cells to temozolomide [J].
Chai, Kit Man ;
Wang, Chih-Yen ;
Liaw, Hung-Jiun ;
Fang, Kuan-Min ;
Yang, Chung-Shi ;
Tzeng, Shun-Fen .
ONCOTARGET, 2014, 5 (21) :10901-10915
[5]   Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models [J].
Clark, Caroline C. ;
Weitzel, Jeffrey N. ;
O'Connor, Timothy R. .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (09) :1948-1958
[6]   Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions [J].
Cook, Peter J. ;
Ju, Bong Gun ;
Telese, Francesca ;
Wang, Xiangting ;
Glass, Christopher K. ;
Rosenfeld, Michael G. .
NATURE, 2009, 458 (7238) :591-U53
[7]   Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations [J].
Dedes, Konstantin J. ;
Wilkerson, Paul M. ;
Wetterskog, Daniel ;
Weigelt, Britta ;
Ashworth, Alan ;
Reis-Filho, Jorge S. .
CELL CYCLE, 2011, 10 (08) :1192-1199
[8]   Alkylation damage in DNA and RNA -: repair mechanisms and medical significance [J].
Drablos, F ;
Feyzi, E ;
Aas, PA ;
Vaagbo, CB ;
Kavli, B ;
Bratlie, MS ;
Peña-Diaz, J ;
Otterlei, M ;
Slupphaug, G ;
Krokan, HE .
DNA REPAIR, 2004, 3 (11) :1389-1407
[9]   BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD [J].
Fiskus, Warren ;
Sharma, Sunil ;
Qi, Jun ;
Shah, Bhavin ;
Devaraj, Santhana G. T. ;
Leveque, Christopher ;
Portier, Bryce P. ;
Iyer, Swaminathan ;
Bradner, James E. ;
Bhalla, Kapil N. .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (10) :2315-2327
[10]   Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells [J].
Fiskus, Warren ;
Sharma, Sunil ;
Qi, Jun ;
Valenta, John A. ;
Schaub, Leasha J. ;
Shah, Bhavin ;
Peth, Karissa ;
Portier, Bryce P. ;
Rodriguez, Melissa ;
Devaraj, Santhana G. T. ;
Zhan, Ming ;
Sheng, Jianting ;
Iyer, Swaminathan P. ;
Bradner, James E. ;
Bhalla, Kapil N. .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (05) :1142-1154